Dapagliflozin ‘equally safe and effective’ for HF in both sexes
Dapagliflozin is similarly beneficial for women and men with heart failure, according to a study published in Circulation.
Xiaowen Wang, MD, from Harvard Medical School in Boston, and colleagues examined the impact of sex on the efficacy and safety of dapagliflozin among 11,007 patients (35% women) in a pre-specified patient-level pooled analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) and Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure (DELIVER) trials.